Sage Journals: Discover world-class research

Abstract

As coronavirus disease (COVID-19) vaccines continue to be administered, dermatologists play a critical role in recognizing and treating the cutaneous manifestations (CM) associated with the vaccines. Adverse cutaneous reactions of COVID-19 vaccines reported in the literature range from common urticarial to rare vesiculobullous reactions. In this study, we performed a (1) scoping review to assess the occurrences of vesicular, papulovesicular, and bullous CMs of COVID-19 vaccines and their respective treatments, and (2) a narrative review discussing other common and uncommon CMs of COVID-19 vaccines. Thirty-six articles were included in the scoping review, and 66 articles in the narrative review. We found that vesicular, papulovesicular, and bullous lesions are infrequent, reported mostly after the first dose of Moderna or Pfizer vaccines. Eleven of the 36 studies reported vesicular reactions consistent with activation or reactivation of the herpes zoster virus. Most vesicular and bullous lesions were self-limited or treated with topical corticosteroids. Other CMs included injection-site, urticarial or morbilliform reactions, vasculitis, toxic epidermal necrolysis, and flaring of or new-onset skin diseases such as psoriasis. Treatments for CMs included topical or oral corticosteroids, antihistamines, or no treatment in self-limited cases. Although most CMs are benign and treatable, the data on the effect of systemic corticosteroids and immunosuppressive therapies on the immunogenicity of COVID-19 vaccines is limited. Some studies report reduced immunogenicity of the vaccines after high-dose corticosteroids use. Physicians may consult local guidelines where available when recommending COVID-19 vaccines to immunosuppressed patients, and when using corticosteroids to manage the CMs of COVID-19 vaccines.

Keywords

COVID-19 vaccine reaction vesiculobullous reaction bullous cutaneous manifestations

Introduction

Since the start of the coronavirus disease (COVID-19) pandemic, dermatologists have played an important role in the diagnosis and management of the varied and now well-described cutaneous manifestations of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As vaccines became rapidly administered across the globe, dermatologists have also been integrally involved in recognizing and treating the cutaneous manifestations of COVID-19 vaccines. While the vaccines available worldwide are considered safe and effective, there are reports of cutaneous reactions after the first and subsequent doses of several vaccines.¹ Some common vaccines approved globally include mRNA-based and viral vector-based vaccines such as Moderna Spikevax^TM (mRNA-1273; referred to as Moderna), Pfizer-BioNTech Comirnaty^TM (BNT162b2; referred to as Pfizer), AstraZeneca Vaxzevria^TM (AZD1222 and ChAdOx1-S [recombinant]; referred to as AstraZeneca), and Janssen (Johnson & Johnson^TM; JNJ-78436735; referred to as Janssen),² Sinovac-Coroavac^TM (referred to as Sinovac),³ and COVAXIN^® (Bharat Biotech BBV152; referred to as Covaxin).⁴

The cutaneous manifestations of the SARS-CoV-2 virus have been reported and summarized extensively in the literature and can be categorized based on their patho-mechanisms into viral exanthems and cutaneous eruptions secondary to systemic consequences.⁵ A meta-analysis of over 2000 articles found that the prevalence of cutaneous manifestations in COVID-19 was 5.69%.⁶ Reported cutaneous manifestations include morbilliform, pseudo-chilblain, pernio-like, urticarial, macular erythema, vesicular, papulosquamous, retiform purpura, livedo, and necrosis, with varying frequencies, which are presented in Supplementary Table 1.^5

-10

While the current knowledge of cutaneous manifestations of SARS-CoV-2 has been reviewed in the literature, data on adverse cutaneous reactions to SARS-CoV-2 vaccines have mostly been reported in case reports or series and/or registry-based retrospective reviews. Cutaneous manifestations are also being reported through the Vaccine Adverse Event Reporting System¹¹ and the American Academy of Dermatology COVID-19 Registry.¹ McMahon et al. have reported several common cutaneous reactions including injection site, urticarial, and morbilliform reactions.¹² A few studies have contrastingly reported uncommon cutaneous manifestations including vesicular, papulovesicular, and bullous-like reactions.¹³

The primary objective of the scoping review is to review the vesicular, papulovesicular, and bullous cutaneous manifestations of COVID-19 vaccines reported in the literature and their frequencies after the first and subsequent doses, and the modalities of treatments utilized. The secondary objective of this paper is to conduct a narrative review of other common and uncommon cutaneous manifestations while highlighting the clinically salient treatment options for Dermatologists and physicians.

Methods

Two concurrent reviews were performed to fulfill the aim of this paper. First, a scoping¹⁴ review was conducted in accordance with the AMSTAR 2 (A MeaSurement Tool to Assess systematic Reviews) reporting guidelines¹⁵ which included patients who received either the first or subsequent doses of COVID-19 vaccines with reported vesicular, papulovesicular, or bullous cutaneous manifestations. A second broader narrative review discussion included articles reporting on all other common and uncommon cutaneous manifestations of COVID-19 vaccines.

Eligibility Criteria

Due to the limited number of randomized controlled trials (RCTs) and controlled clinical trials (CCTs) reporting the cutaneous manifestations of COVID-19 vaccines, all peer-reviewed article types were included in both the scoping and narrative reviews. These included case reports, case series, observational, retrospective, registry-based retrospective reviews, RCTs, and CCTs. Resultantly, we were unable to conduct a quality assessment of the studies included in the review due to the high level of heterogeneity and the inclusion of non-interventional and case report studies. For both the scoping and narrative reviews, the study subjects must have received the COVID-19 vaccine. There were no restrictions on the type of vaccine in the scoping review; however, the narrative review discussion was focused on the vaccines approved by Health Canada (Moderna, Pfizer, AstraZeneca, and Janssen).² No date restrictions were applied and only studies reported in English were included in both reviews. Studies were excluded from the narrative review if (1) they did not report the cutaneous manifestations after the first or subsequent vaccine doses, (2) they did not clearly define or describe the cutaneous manifestation and its onset, or if (3) the studies did not include vaccines approved by Health Canada.²

During the full-text screening process, articles with a focus on cutaneous manifestations of COVID-19 vaccines were retrieved for the narrative review. These included registry studies, retrospective reviews, case reports, and case series. Due to the broad spectrum of common cutaneous manifestations reported in the literature, we excluded articles that did not discuss vaccines approved by Health Canada.

Outcomes

The following outcomes were assessed:

Type of cutaneous reaction

Frequency of cases reported after each dose

Time to onset after the vaccine

Duration of cutaneous reaction

Treatment of the reaction

Electronic Searches

The search was conducted using EMBASE, Web of Science, and PubMed from their inception to the present on January 18th, 2022. Articles were screened to identify additional references. The following search terms were used: vesiculopapular, papulovesicular, papular, vesicular, bullae, bullous, cutaneous reactions, skin reactions, dermatology reactions, cutaneous side effects, adverse reactions, and vaccination, vaccine, Pfizer-BioNTech Comirnaty, Moderna Spikevax, Pfizer-BioNTech, mRNA-1273, Moderna, Pfizer, and SARS-CoV-2, coronavirus, Covid-19, Covid.

Data Collection and Extraction

Titles, abstracts, and full-text articles were dual-screened by two reviewers (F.M. and A.L.) on the Covidence platform.¹⁶ Data were extracted by three reviewers (F.M., A.L., J.C.). Data were presented via tables and described qualitatively. Due to the heterogeneity of the study types, populations, and vaccines administered a combined analysis of the data or meta-analysis could not be performed.

Results

The scoping review yielded 1984 articles, of which 793 were duplicates (Supplementary Figure 1). For the scoping review, the titles and abstracts of 1191 articles were screened, and 203 articles were included in the full-text review. Of these, a total of 36 articles were included in the scoping review. The reason for exclusion included no discussion of vesicular, papulovesicular, or bullous reactions (n = 167). Twenty-seven^{12,13,17

-41} of the 36 articles described nonspecific vesicular, papulovesicular, or bullous reactions, compared to eleven^{18,24,42

-50} discussing vesicular eruptions in concordance with new-onset or reactivation of the herpes zoster virus. During the screening process, a total of 66 articles discussing other cutaneous manifestations were retrieved from the full-text screening to extract data in tabular formats and were discussed in our narrative review.

Vesicular and Papulovesicular Reactions

Vesicular and papulovesicular reactions have been reported after the Moderna, Pfizer, AstraZeneca, and Sinovac vaccines (Supplementary Table 2). Four studies including RCTs, and case series reported vesicular or papulovesicular reactions after the first Moderna vaccine and three after the second dose.^12,17

-20 Cases of vesicular reactions ranged from <0.1% (15185 total first doses) to 4.8% (147 total first doses) after the first dose, compared to 1% (102 total second doses) to 5% (40 total second doses) after the second dose. The time to onset after the first and second doses ranged from 6.4 to 28 days and 3-48 days, respectively. Most of these reactions spontaneously resolved around 7 days.

Six studies similarly reported vesicular and papulovesicular reactions after the first dose of Pfizer compared to four reporting it after the second dose.^{12,18,20

-23} Freeman et al. reported up to 9.6% (114 total first doses) and 10% (140 total second doses) of cases after the first and second doses of Pfizer, respectively.¹⁸ Vaccaro et al. reported a case series of 8 patients who developed vesicular rashes after the first Pfizer or AstraZeneca doses combined, occurring around 4-12 hours after the vaccines.²³ The reactions persisted for up to 14 days. Tammaro et al. similarly reported two cases of vesicular reactions after the second Pfizer dose occurring in 64 and 56-year-old females.²² The reactions consisted of round erythematous, painful, and pruritic nodules and vesicles.

Cases of vesicular reactions have also been reported after the first dose of the AstraZeneca vaccine in 4 studies.^20,24
-26 Up to 8.4% (95 total first dose AstraZeneca) cases were reported after the first AstraZeneca vaccine, and these reactions generally persisted for 3 days. Rerknimitr et al. also reported vesicular lesions after both the first and second doses of Sinovac.²⁴

Bullous Reactions

Most of the bullous reactions from COVID-19 vaccines were reported through case reports and case series (Supplementary Table 2). Five studies reported bullous reactions after the first and second doses of Moderna.^{13,18,27

-30} Amongst the patients receiving the Moderna vaccine, 3.1% of 447 patients developed bullous eruptions after the first Moderna dose compared to 2.6% of 223 patients after the second dose. Two cases had worsened bullous eruptions after the second Moderna dose. Most of the bullous reactions resolved within 2-3 weeks. The onset of eruptions after the vaccines averaged around 9.9 and 5.6 days after the first and second doses of Moderna respectively.

Bullous reactions after the Pfizer vaccine have mostly been described in 13 studies including 12 case reports or case series and 1 registry study, 4 of which were confirmed cases of bullous pemphigoid.^{13,18,23,27,28,31

-38} Upon combining the patients receiving the Pfizer vaccines, 13.5% of 178 cases developed bullous eruptions after the first dose reported in 12 studies compared to 13.5% of 156 cases after the second dose reported in 8 studies. Four cases had reactions after both the first and second vaccines and 2 cases had ongoing or unresolved lesions when receiving the second dose, which persisted after the second dose as well. Juay et al. reported 3 cases including dyshidrotic eczema, acute generalized pustulosis, and bullous pemphigoid.³¹ The average time to onset after the first and second dose was 8.5 and 3.95 days, respectively. Most of these lesions resolved by 3 weeks after the vaccine doses with 4 cases ongoing at 6 weeks or more.

Vaccaro et al. reported 2 cases of vesicular lesions coalescing into a single bulla after the AstraZeneca or Pfizer vaccines.²³ This study did not specify whether the Pfizer or AstraZeneca vaccines caused the bullous reaction; however, Vaccaro et al. do note that 12 injection‐site skin reactions were described after the Pfizer vaccine and 16 after the AstraZeneca vaccine out of a total sample size of 16217 vaccinated with Pfizer and 1377 vaccinated with AstraZeneca.²³ Three other case reports describe bullous reactions after the first (2 cases) and second (1 case) doses of Astrazeneca.^39
-41 Biopsy findings from 2 of the case reports from AstraZeneca vaccine reactions demonstrated linear IgA bullous dermatosis and a generalized bullous fixed drug eruption on the abdomen, trunk thighs, and extremities.^40,41

Varicella-Zoster Virus (VZV) Reactions

Five^18,24,42
-44 studies have reported new-onset or activation of VZV after Pfizer, AstraZeneca, or Sinovac vaccines, which have presented as blisters and vesicles with maculopapular rashes (Supplementary Table 3).^{18,24,42

-53} Most reactions occurred after the first dose, presenting 4.6 days after the vaccine and lasting for up to 2 weeks. Six studies^45

-50 reported reactivation of VZV in patients with previous varicella cutaneous eruptions presenting after 9.8 and 6.8 days after the first and second doses of COVID-19 vaccines, respectively. Reactivations were most commonly associated with the second dose of the Pfizer vaccine. VZV reactions were mostly treated with antiviral therapies.

Treatment of Vesicular, Papulovesicular, and Bullous-Like Reactions

Most vesicular or papulovesicular eruptions were self-limited and resolved within 7 days. Reported outpatient treatments included topical corticosteroids and antihistamines. Only one case required hospitalization for generalized bullous erythema multiforme; however, the authors do not specify the management and outcome of this patient.¹⁹ One case of herpes zoster reactivation after Pfizer initially did not respond to 40 mg of prednisone, 25 mg of hydroxyzine, and 2% mupirocin ointment but later self-regressed (Supplementary Tables 2 and 3).⁴⁷

The majority of bullous reactions were managed with oral prednisone, topical corticosteroids, and emollients. Combinations of topical or oral steroids and mycophenolate mofetil or doxycycline, niacinamide, and antihistamines were also reported with success. A case of dyshidrotic eczema with bullae was treated with topical betamethasone dipropionate ointment.³¹

Narrative Review of Common and Uncommon Cutaneous Manifestations

In addition to vesicular, papulovesicular, and bullous reactions, several other common and uncommon cutaneous manifestations have been reported. Uncommon manifestations included those reported merely in case reports or small case series and/or reported in less than 5 articles we screened.

Common Cutaneous Manifestations

Common cutaneous manifestations are summarized in Supplementary Table 4.^{12,17

-24,27,43,44,54

-77} These included delayed large local arm reactions, local injection site reactions, urticaria or urticarial reactions, morbilliform or maculopapular eruptions, pityriasis rosea (PR)-like eruptions, pernio or chilblains, dermatitis, cutaneous small vessel vasculitis (CSVV), ecchymosis, petechiae, purpura, and lymphadenopathy. The reactions were mainly reported with Moderna and Pfizer and occasionally with AstraZeneca, Sinovac, and Covaxin.

Many of these common reactions were reported through randomized controlled trials, registry studies, case series, or observational studies. McMahon et al. reported a registry-based study that gathered information about cutaneous manifestations following Pfizer and Moderna COVID-19 vaccinations.¹² They found that delayed large local reactions were the most common, with pernio/chilblains and PR-like reactions being less common.

Most urticarial reactions from Moderna occurred around 2-28 days after the first dose and lasted around 2-30 days. From the second dose, urticarial reactions occurred around 2 days after the vaccination and lasted around 2-5 days. Urticarial reactions from Pfizer occurred around 20 minutes to 10 days after the first dose, lasting around 12 hr up to 28 days, and occurred from 30 minutes to 5 days after the second dose, lasting around 12 hr up to 14 days (Supplementary Table 4).

Morbilliform or maculopapular eruptions were reported to be caused by Moderna, Pfizer, AstraZeneca, and Sinovac. The reactions occurred around 3-28 days after the first dose of Moderna, lasting 4-10 days, and occurred around 1-2 days after the second dose, lasting from around 2.5-35 days. The reaction occurred around 1-7.5 days after the first dose of Pfizer, lasting around 4-12 days, and occurred around 4 hr to 2 days after the second dose, lasting around 2.5 days. There were a handful of morbilliform or maculopapular reactions after the AstraZeneca vaccination, mostly after the first dose (Supplementary Table 4).

Dermatitis was also reported after Moderna and Pfizer vaccination occurring around 5 days after the first and second doses of Moderna. With Pfizer, the reaction occurred 2.5-21 days after the first dose, lasting up to several weeks, and occurred 4-12 days after the second dose, lasting 8-21 days.

Flares of Pre-Existing Dermatoses

Flares of pre-existing psoriasis were also reported, predominantly after the Pfizer vaccine,^21,51
-53 in addition to cases of vasculitis (Supplementary Table 3). One case of worsening psoriasis was reported after the first Moderna dose compared to 6 cases after the second dose.⁵¹ After the Pfizer vaccine, 2 cases of either pustular palmoplantar psoriasis or de novo nail psoriasis were reported after both first and second doses.^52,53 Wei et al. further presented 57 flares of psoriasis after the first doses of Pfizer, Moderna, and Janssen vaccines combined compared to 19 flares reported after the second dose, 5 of which recurred after the first and second doses of Moderna or Pfizer (Supplementary Table 3).⁵¹

Uncommon Cutaneous Manifestations

Several cases of uncommon cutaneous manifestations of vaccines have been reported and are summarized in Supplementary Table 5.^{18,21,24,43,51,68,78

-105} These include toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome (SJS), skin necrosis, angioedema, edematous infiltrated plaques, Sweet syndrome, acute generalized exanthematous pustulosis, erythema multiforme (EM), erythema nodosum (EN), radiation recall dermatitis, papular acrodermatitis, cutaneous lichen planus (LP), new-onset and exacerbation of cutaneous lupus erythematosus (cLE), T-cell predominant cutaneous lymphoid hyperplasia, lichenoid reactions, pityriasis lichenoides et varioliformis Acuta (PLEVA), molluscum contagiosum, cutaneous mucormycosis at the injection site, livedo racemosa, fixed drug eruption (FDE), vulvar aphthae, purpura due to Evan’s syndrome, and dermatomyositis. New-onset psoriasis and vitiligo have also been reported. These reactions were reported after the first doses of the Pfizer vaccine followed by Moderna then AstraZeneca. It is unclear whether this is because more people have received their first dose than subsequent doses. Five reactions initiated after the first dose recurred or exacerbated after the second dose including vitiligo, cLE, PLEVA, and angioedema. Five patients were advised not to receive the second dose of the vaccine after reacting to the first dose or chose not to themselves. The time to onset for all uncommon reactions was around 7.5 days after the administration of the vaccines.

Wei et al. reported one case of new-onset psoriasis after the second dose of Moderna in a case series, and 22 cases (6 guttate type psoriasis) after the first dose of Pfizer, Moderna, and Janssen in a retrospective review of the CDC VAERS (Centre for Disease Control and Prevention - The Vaccine Adverse Event Reporting System) reports from December 2020 to August 2021.⁵¹ Freeman et al. have also reported several new-onset dermatoses after the first and second doses of Moderna and Pfizer including lichen planus, psoriasis, and morphea.¹⁸

Reactions to previously placed hyaluronic acid soft tissue fillers have been reported after Pfizer’s first and second doses (3 cases) and after the second dose of Moderna (1 case). Most of the reactions were self-limited resolving within 1 week, with 2 cases requiring either methylprednisolone or removal of the filler product (Supplementary Table 3).^103
-105

Treatment of Non-Vesiculobullous Reactions

Reported treatments for common cutaneous manifestations included topical corticosteroids, oral corticosteroids taper such as prednisolone or prednisone, antihistamines, or no treatment in self-limiting cases. Vaccine-induced psoriasis was reported to improve with topical steroids, apremilast, phototherapy, and biologics including risankizumab and tildrakizumab. Most reactions improved with treatment (Supplementary Table 4). Reactions that did not improve included an urticarial reaction after Moderna treated with topical mometasone,⁶² a case of acute generalized exanthematous pustulosis managed with diphenhydramine and topical hydrocortisone cream,⁸⁴ and a case of cLE after Pfizer which initially did not respond to oral prednisolone 10 mg but responded to pulse therapy with 60 mg of prednisolone tapered over 3 weeks with topical mometasone ointment.⁹³ Cases of common or uncommon manifestations which were hospitalized included PR-like eruptions, CSVV, lichenoid reactions, TEN, and SJS (Supplementary Table 5).

Discussion of Treatment Considerations and Guidance

Corticosteroids are most commonly reported as the management of cutaneous COVID-19 vaccine reactions; however, the immunosuppressive impacts of systemic corticosteroids on the immunogenic response to vaccination should be considered prior to treatment.^106,107 Recent studies have assessed the immunogenicity of COVID-19 vaccines in immunocompromised patients; however, data is limited on patients receiving corticosteroids for a cutaneous manifestation of the COVID-19 vaccine. The 2021 American College of Rheumatology (ACR) guidelines¹⁰⁸ suggested that conventional and targeted immunomodulatory or immunosuppressive medications should be held for one to 2 weeks (as disease activity allows) after each COVID-19 vaccine dose. There was no consensus as to whether a vaccine response might be blunted in prednisone doses of more than 20 mg/day. Deepak et al. showed that corticosteroids independent of their doses had a 10-fold reduction in humoral responses to COVID-19 vaccines when compared to the immunocompetent controls.¹⁰⁹ However, Yang et al. found that short-term use of low-dose corticosteroids (median total of 30 mg prednisolone equivalent) did not hinder the vaccine’s immunogenicity but rather reduced the vaccine’s reactogenicity.¹¹⁰ Reactogenicity is defined as the local and systemic complications of the vaccine.

It has previously been reported that doses of up to 20 mg/day of prednisone or equivalents do not suppress responses to inactivated vaccines, as these doses are not considered immunosuppressive.^106,111 Doses of 20 mg/day or more of corticosteroids for 2 or more weeks or more than 40 mg for more than 1 week are considered immunosuppressive.^106,107

Other immunosuppressive agents including B-cell depletion agents also reduced the immunogenicity of COVID-19 vaccines up to 36-fold, especially when vaccinated within 6 months of B-cell depleting therapy.¹⁰⁹ JAK inhibitors and antimetabolites including methotrexate also blunted antibody titers in a multivariate regression analysis. TNF inhibitors, IL-12/23 inhibitors, and integrin inhibitors had a modest impact on antibody formation and neutralization. Notably, patients infected with COVID-19 receiving B-cell depletion therapies have increased mortality compared to patients on methotrexate. Thus, B-cell depleting agents may need to be held or additional COVID-19 vaccines may be required.¹⁰⁹ Furthermore, although evidence is limited, current guidelines suggest continuing biologics, small molecules, or antimetabolites in inflammatory bowel disease and psoriasis patients when administering the COVID-19 vaccine. Certain immunosuppressants including methotrexate and JAK inhibitors should be ideally held for 1 week after each COVID-19 vaccine dose for patients with well-controlled diseases.¹⁰⁹ Current guidelines in inflammatory bowel disease and psoriasis do not suggest holding biologics, small molecules, or antimetabolites prior to vaccination against COVID-19; however, this could be decided on a case-by-case basis considering both the half-life of the drug and the clinical disease activity.^112,113

Other immunocompromised groups include organ transplant recipients and patients with cancers. Previous studies showed that only 47.5% of liver transplant recipients had positive antibodies against COVID-19 after the Pfizer vaccine compared to 100% of the control group. Predictors for the negative response included treatment with high-dose prednisone in the last 12 months.¹¹⁴ A systematic review and meta-analysis similarly found that seroconversion after the first dose of mRNA or non-mRNA-based vaccines was half as likely in patients with hematological cancers, immune-mediated inflammatory disorders, and solid cancers, and 16 times less likely in organ transplant recipients. The seroconversion after subsequent second and third doses of the vaccine improved across all immunocompromised patients.¹¹⁵ Thus, it was concluded that targeted interventions for immunocompromised patients, including a third booster dose of COVID-19 vaccines should be administered.

Limitations and Next Steps

This scoping review is limited to papulovesicular and vesiculobullous cutaneous manifestations of COVID-19 vaccines. Due to limited studies reporting such manifestations, we included all studies we identified and did not score for quality. As such, there were large variations in sample sizes and heterogeneity in how the outcomes were reported; thus, data synthesis was difficult. While we discuss other cutaneous manifestations in a narrative review style, these studies were identified from our focused search strategy for the scoping review. We did not include all studies reporting all cutaneous manifestations of COVID-19; however, given the broad nature of this topic, a scoping or systematic review on all cutaneous manifestations of COVID-19 vaccines would be unfeasible. Given many studies did not provide patient’s comorbidities or medication histories and we did not record these outcomes, it is difficult to determine whether some reported cutaneous manifestations are truly secondary to COVID-19 vaccines or developed concurrently, spontaneously or due to other comorbidities or drug reactions. Future studies may control for population, vaccine, and temporal variations by conducting prospective and/or retrospective studies assessing cutaneous manifestations in a large relatively healthy population receiving the same vaccine around the same time. Ideally, all patients would be followed at specific time points. The pathophysiology underlying several cutaneous manifestations should also be elucidated.

Conclusion

In this review, we explored cutaneous manifestations of COVID-19 vaccines with a particular focus on vesicular, papulovesicular, and bullous lesions. Bullous and papulovesicular reactions are uncommon cutaneous manifestations of the COVID-19 vaccines, reported in a total of 36 case reports or case series occurring more often after the first dose of Moderna or Pfizer vaccines. Eleven of these 36 studies reported activation or reactivation of the herpes zoster virus after the COVID-19 vaccines, which presented with vesicular and papulovesicular lesions. Most of these lesions were self-limited or were treated with topical corticosteroids alone.

Across 66 studies, we found a total of 12 common CM and 17 uncommon CM. Common CM included local arm reactions, urticaria or urticarial reactions, morbilliform eruptions, PR-like eruptions, pernio or chilblains, dermatitis, leukocytoclastic vasculitis, ecchymosis, petechiae, purpura, and lymphadenopathy. Uncommon CM included TEN, SJS, skin necrosis, angioedema, infiltrated plaques, Sweet’s syndrome, acute generalized exanthematous pustulosis, EM, EN, radiation recall dermatitis, papular acrodermatitis, LP, new-onset and exacerbation of cutaneous lupus erythematosus, T-cell predominant cutaneous lymphoid hyperplasia, lichenoid reactions, PLEVA, molluscum contagiosum, cutaneous mucormycosis, livedo racemosa, FDE, vulvar aphthae, purpura due to Evan’s syndrome, and dermatomyositis. The reactions were most commonly associated with the first doses of Moderna and Pfizer vaccines, most of which were self-limited and managed with oral or topical corticosteroids. By reviewing the cutaneous manifestations associated with COVID-19 vaccines, we aim to help physicians recognize and manage patients presenting with manifestations.

Supplemental Material

Table S1 - Supplemental material for Vesiculobullous and Other Cutaneous Manifestations of COVID-19 Vaccines: a Scoping and Narrative Review

Supplemental material, Table S1, for Vesiculobullous and Other Cutaneous Manifestations of COVID-19 Vaccines: a Scoping and Narrative Review by Farhan Mahmood, Janelle Cyr, Amy Li, Jennifer Lipson, Melanie Pratt and Jennifer Beecker in Journal of Cutaneous Medicine and Surgery

Footnotes

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iD

Farhan Mahmood

Supplemental Material

Supplemental material for this article is available online.

References

Covid-19 dermatology registry [Internet] . American Academy of Dermatology. cited 2022 Jun 3. https://www.aad.org/member/practice/coronavirus/registry

US Department of Health and Human Services . Stay up to date with covid-19 vaccines including boosters [Internet]. Centers for Disease Control and Prevention. Centers for Disease Control and Prevention; 2022. cited 2022 May 2. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/stay-up-to-date.html#about-vaccines

The Sinovac-CoronaVac COVID-19 vaccine: What you need to know [Internet] . World Health Organization; 2022. cited 2022 Nov 22. https://www.who.int/news-room/feature-stories/detail/the-sinovac-covid-19-vaccine-what-you-need-to-know?gclid=Cj0KCQiAg_KbBhDLARIsANx7wAwzVBQGAr6OiP4aOk9lCxy0KgzbUS8jCmRpGvhmeKyt92fVQDehe4YaAtRUEALw_wcB

The Bharat Biotech BBV152 COVAXIN vaccine against COVID-19: What you need to know [Internet] . World Health Organization; 2022. 2022 Nov 22. https://www.who.int/news-room/feature-stories/detail/the-bharat-biotech-bbv152-covaxin-vaccine-against-covid-19-what-you-need-to-know

Suchonwanit

Leerunyakul

Kositkuljorn

. Diagnostic and prognostic values of cutaneous manifestations in COVID-19. Dermatol Ther. 2020;33(4):e13650 doi:10.1111/dth.13650

32445279

Rajan M

Kumar-M

Bhardwaj

. The trend of cutaneous lesions during COVID-19 pandemic: lessons from a meta-analysis and systematic review. Int J Dermatol. 2020;59(11):1358-1370.doi:10.1111/ijd.15154

32936462

Galván Casas

Catal

Carretero Hernández

et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol. 2020;183(1):71-77.doi:10.1111/bjd.19163

32348545

Freeman

EE.

McMahon

DE.

Lipoff

et al. Pernio-like skin lesions associated with COVID-19: a case series of 318 patients from 8 countries. J Am Acad Dermatol. 2020;83(2):486-492.doi:10.1016/j.jaad.2020.05.109

32479979

Rubio‐Muniz

CA.

Puerta‐Peña

Falkenhain‐López

et al. The broad spectrum of dermatological manifestations in COVID‐19: clinical and histopathological features learned from a series of 34 cases. J Eur Acad Dermatol Venereol. 2020;34(10):e574-e576.doi:10.1111/jdv.16734

32526040

10.

Ocampo-Candiani

Ramos-Cavazos

CJ.

Arellano-Mendoza

et al. International registry of dermatological manifestations secondary to COVID-19 infection in 347 Hispanic patients from 25 countries. Int J Dermatol. 2021;60(8):956-963.doi:10.1111/ijd.15632

33963765

11.

Vaccine Adverse Event Reporting System [Internet] . Centers for Disease Control and Prevention. Centers for Disease Control and Prevention; 2021. cited 2022 Jun 3. https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/vaers/index.html

12.

McMahon

DE.

Amerson

Rosenbach

et al. Cutaneous reactions reported after Moderna and pfizer COVID-19 vaccination: a registry-based study of 414 cases. J Am Acad Dermatol. 2021;85(1):46-55.doi:10.1016/j.jaad.2021.03.092

33838206

13.

Tomayko

MM.

Damsky

Fathy

et al. Subepidermal blistering eruptions, including bullous pemphigoid, following COVID-19 vaccination. J Allergy Clin Immunol. 2021;148(3):750-751.doi:10.1016/j.jaci.2021.06.026

34275656

14.

Daudt

HML.

van Mossel

Scott

. Enhancing the scoping study methodology: a large, inter-professional team’s experience with Arksey and O’Malley’s framework. BMC Med Res Methodol. 2013;13(1):48 doi:10.1186/1471-2288-13-48

23522333

15.

Shea

BJ.

Reeves

BC.

Wells

et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358:j4008 doi:10.1136/bmj.j4008

28935701

16.

. Covidence systematic review software, Veritas Health Innovation, Melbourne, Australia. www.covidence.org

17.

Baden

LR.

El Sahly

HM.

Essink

et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403-416.doi:10.1056/NEJMoa2035389

33378609

18.

Freeman

EE.

Sun

McMahon

et al. Skin reactions to COVID-19 vaccines: an American Academy of Dermatology/International League of dermatological societies registry update on reaction location and COVID vaccine type. J Am Acad Dermatol. 2022;86(4):e165-e167.doi:10.1016/j.jaad.2021.11.016

34800601

19.

Burlando

Herzum

Micalizzi

Cozzani

Parodi

. Cutaneous reactions to COVID-19 vaccine at the dermatology primary care. Immun Inflamm Dis. 2022;10(2):265-271.doi:10.1002/iid3.568

34837354

20.

Català

Muñoz-Santos

Galván-Casas

et al. Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases. Br J Dermatol. 2022;186(1):142-152.doi:10.1111/bjd.20639

34254291

21.

Niebel

Wenzel

Wilsmann-Theis

Ziob

Wilhelmi

Braegelmann

. Single-center clinico-pathological case study of 19 patients with cutaneous adverse reactions following COVID-19 vaccines. Dermatopathology. 2021;8(4):463-476.doi:10.3390/dermatopathology8040049

34698094

22.

Tammaro

Adebanjo

GAR.

Parisella

FR.

De Marco

Rello

. Local reactions to the second dose of the BNT162 COVID ‐19 vaccine. Dermatol Ther. 2021;34(4):e15000 doi:10.1111/dth.15000

34031953

23.

Vaccaro

Bertino

Squeri

et al. Early atypical injection‐site reactions to COVID‐19 vaccine: a case series. J Eur Acad Dermatol Venereol. 2022;36(1):e24-e26.doi:10.1111/jdv.17683

34547113

24.

Rerknimitr

Puaratanaarunkon

Wongtada

et al. Cutaneous adverse reactions from 35,229 doses of Sinovac and AstraZeneca COVID-19 vaccination: a prospective cohort study in healthcare workers. J Eur Acad Dermatol Venereol. 2022;36(3):e158-e161.doi:10.1111/jdv.17761

34661934

25.

Pourani

MR.

Shahidi Dadras

Salari

Diab

Namazi

Abdollahimajd

. Cutaneous adverse events related to COVID-19 vaccines: a cross-sectional questionnaire-based study of 867 patients. Dermatol Ther. 2022;35(2):e15223 doi:10.1111/dth.15223

34820975

26.

Adya

KA.

Inamadar

AC.

Albadri

. Post Covid-19 vaccination papulovesicular pityriasis rosea-like eruption in a young male. Dermatol Ther. 2021;34(5):e15040 doi:10.1111/dth.15040

34165237

27.

Larson

Seidenberg

Caplan

Brinster

NK.

Meehan

SA.

Kim

. Clinical and histopathological spectrum of delayed adverse cutaneous reactions following COVID ‐19 vaccination. J Cutan Pathol. 2022;49(1):34-41.doi:10.1111/cup.14104

34292611

28.

Damiani

Pacifico

Pelloni

Iorizzo

. The first dose of COVID-19 vaccine may trigger pemphigus and bullous pemphigoid flares: is the second dose therefore contraindicated? J Eur Acad Dermatol Venereol. 2021;35(10):e645-e647.doi:10.1111/jdv.17472

34169578

29.

Khalid

Lipka

Becker

. Moderna COVID-19 vaccine induced skin rash. Vis J Emerg Med. 2021;25:101108.doi:10.1016/j.visj.2021.101108

34423142

30.

Kong

Cuevas-Castillo

Nassar

et al. Bullous drug eruption after second dose of mRNA-1273 (Moderna) COVID-19 vaccine: case report. J Infect Public Health. 2021;14(10):1392-1394.doi:10.1016/j.jiph.2021.06.021

34294590

31.

Juay

Chandran

. Three cases of vesiculobullous non‐IgE‐mediated cutaneous reactions to tozinameran (Pfizer‐BioNTech COVID‐19 vaccine). Acad Dermatol Venereol. 2022;35(12):e855-e857.doi:10.1111/jdv.17581

32.

Coto-Segura

Fernández-Prada

Mir-Bonafé

et al. Vesiculobullous skin reactions induced by COVID-19 mRNA vaccine: report of four cases and review of the literature. Clin Exp Dermatol. 2022;47(1):141-143.doi:10.1111/ced.14835

34236711

33.

Gambichler

Hamdani

Budde

et al. Bullous pemphigoid after SARS-CoV-2 vaccination: spike-protein-directed immunofluorescence confocal microscopy and T-cell-receptor studies. Br J Dermatol. 2022;186(4):728-731.doi:10.1111/bjd.20890

34773638

34.

Dell’Antonia

Anedda

Usai

Atzori

Ferreli

. Bullous pemphigoid triggered by COVID-19 vaccine: rapid resolution with corticosteroid therapy. Dermatol Ther. 2022;35(1):e15208. doi:10.1111/dth.15208

34786801

35.

Young

Mercieca

Ceci

Pisani

Betts

Boffa

. A case of bullous pemphigoid after the SARS-CoV-2 mRNA vaccine. J Eur Acad Dermatol Venereol. 2022;36(1):e13-e16.doi:10.1111/jdv.17676

34547137

36.

Pauluzzi

Stinco

Errichetti

. Bullous pemphigoid in a young male after COVID‐19 mRNA vaccine: a report and brief literature review. Acad Dermatol Venereol. 2022;36(4):e257-e259.doi:10.1111/jdv.17891

37.

Pérez-López

Moyano-Bueno

Ruiz-Villaverde

. Penfigoide ampolloso y vacuna COVID-19. Medicina Clínica. 2021;157(10):e333-e334.doi:10.1016/j.medcli.2021.05.005

38.

Nakamura

Kosano

Sakai

et al. Case of bullous pemphigoid following coronavirus disease 2019 vaccination. J Dermatol. 2021;48(12):e606-e607.doi:10.1111/1346-8138.16170

34545973

39.

Agharbi

F-Z.

Eljazouly

Basri

et al. Bullous pemphigoid induced by the AstraZeneca COVID-19 vaccine. Ann Dermatol Venereol. 2022;149(1):56-57.doi:10.1016/j.annder.2021.07.008

34686374

40.

Hali

Kerouach

Alatawna

Chiheb

Lakhdar

. Linear IgA bullous dermatosis following Oxford AstraZeneca COVID‐19 vaccine. Clin Exp Dermatol. 2022;47(3):611-613.doi:10.1111/ced.15007

34762342

41.

Wantavornprasert

Noppakun

Klaewsongkram

Rerknimitr

. Generalized bullous fixed drug eruption after Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccination. Clin Exp Dermatol. 2022;47(2):428-432.doi:10.1111/ced.14926

34482558

42.

van Dam

CS.

Lede

Schaar

Al-Dulaimy

Rösken

Smits

. Herpes zoster after COVID vaccination. Int J Infect Dis. 2021;111:169-171.doi:10.1016/j.ijid.2021.08.048

34428545

43.

Mehta

Handa

Malhotra

et al. Erythema nodosum, zoster duplex and pityriasis rosea as possible cutaneous adverse effects of Oxford-AstraZeneca COVID-19 vaccine: report of three cases from India. J Eur Acad Dermatol Venereol. 2022;36(1):e16-e18.doi:10.1111/jdv.17678

34547126

44.

Agarwal

Panda

Behera

BK.

Jena

. Benign cutaneous reactions post-COVID-19 vaccination: a case series of 16 patients from a tertiary care center in India. J Cosmet Dermatol. 2022;21(1):30-33.doi:10.1111/jocd.14592

34762355

45.

Atiyat

Elias

Kiwan

Shaaban

HS.

Slim

. Varicella-zoster virus reactivation in AIDS patient after pfizer-BioNTech COVID-19 vaccine. Cureus. 2021;13(12):e20145 doi:10.7759/cureus.20145

35003978

46.

Nanova

Zlotogorski

Ramot

. Recurrent varicella following SARS-CoV-2 vaccination with BNT162b2. Int J Dermatol. 2021;60(9):1148-1149.doi:10.1111/ijd.15660

33998677

47.

Santovito

LS.

Pinna

. A case of reactivation of varicella–zoster virus after BNT162b2 vaccine second dose? Inflamm Res. 2021;70(9):935-937.doi:10.1007/s00011-021-01491-w

34390376

48.

Fukuoka

Kibe

Tubbs

RS.

Iwanaga

. Oral herpes zoster infection following COVID-19 vaccination: a report of five cases. Cureus. 2021;13(11):e19433 doi:10.7759/cureus.19433

34909338

49.

Shah

Baral

Chamlagain

Murarka

Raj Adhikari

Sharma Paudel

. Reactivation of herpes zoster after vaccination with an inactivated vaccine: a case report from Nepal. Clin Case Rep. 2021;9(12):e05188 doi:10.1002/ccr3.5188

34934501

50.

Aksu

SB.

Öztürk

. A rare case of shingles after COVID-19 vaccine: is it a possible adverse effect? Clin Exp Vaccine Res. 2021;10(2):198 doi:10.7774/cevr.2021.10.2.198

34222134

51.

Wei

Kresch

Elbogen

Lebwohl

. New onset and exacerbation of psoriasis after COVID-19 vaccination. JAAD Case Rep. 2022;19:74-77.doi:10.1016/j.jdcr.2021.11.016

34869811

52.

Piccolo

Russo

Mazzatenta

et al. COVID vaccine-induced pustular psoriasis in patients with previous plaque type psoriasis. J Eur Acad Dermatol Venereol. 2022;36(5):10.1111/jdv.17918 doi:10.1111/jdv.17918

35015916

53.

Ricardo

JW.

Lipner

. Case of de novo nail psoriasis triggered by the second dose of Pfizer-BioNTech BNT162b2 COVID-19 messenger RNA vaccine. JAAD Case Rep. 2021;17:18-20.doi:10.1016/j.jdcr.2021.09.009

34611542

54.

Parés-Badell

Martínez-Gómez

Pinós

et al. Local and systemic adverse reactions to mRNA COVID-19 vaccines comparing two vaccine types and occurrence of previous COVID-19 infection. Vaccines. 2021;9(12):1463.doi:10.3390/vaccines9121463

34960209

55.

Valera-Rubio

MM.

Sierra-Torres

MIM.

Castillejo García

et al. Adverse events reported after administration of BNT162b2 and mRNA-1273 COVID-19 vaccines among hospital workers: a cross-sectional survey-based study in a Spanish hospital. Expert Rev Vaccines. 2022;21(4):533-540.doi:10.1080/14760584.2022.2022478

34986076

56.

Sidlow

JS.

Reichel

Lowenstein

. Localized and generalized urticarial allergic dermatitis secondary to SARS-CoV-2 vaccination in a series of 6 patients. JAAD Case Rep. 2021;14:13-16.doi:10.1016/j.jdcr.2021.05.018

34109263

57.

Ripabelli

Tamburro

Buccieri

et al. Active surveillance of adverse events in healthcare workers recipients after vaccination with COVID-19 BNT162b2 vaccine (Pfizer-BioNTech, Comirnaty): a cross-sectional study. J Community Health. 2022;47(2):211-225.doi:10.1007/s10900-021-01039-3

34628568

58.

Cuschieri

Borg

Agius

Souness

Brincat

Grech

. Adverse reactions to Pfizer‐BioNTech vaccination of healthcare workers at Malta’s state hospital. Int J Clin Pract. 2021;75(10):e14605 doi:10.1111/ijcp.14605

34228863

59.

Almufty

HB.

Mohammed

SA.

Abdullah

AM.

Merza

. Potential adverse effects of COVID-19 vaccines among Iraqi population; a comparison between the three available vaccines in Iraq; a retrospective cross-sectional study. Diabetes Metab Syndr. 2021;15(5):102207.doi:10.1016/j.dsx.2021.102207

34280733

60.

Holmes

GA.

Desai

Limone

et al. A case series of cutaneous COVID-19 vaccine reactions at Loma Linda university department of dermatology. JAAD Case Rep. 2021;16:53-57.doi:10.1016/j.jdcr.2021.07.038

34423106

61.

Chopra

Kim

Flamm

. Cutaneous skin manifestation following messenger RNA Moderna SARS-CoV-2 vaccine with dermal hypersensitivity reaction histopathology. JAAD Case Rep. 2021;16:24-25.doi:10.1016/j.jdcr.2021.07.039

34414254

62.

Guénin

SH.

Kresch

Elbogen

Lebwohl

. Cutaneous reaction reported after third Moderna COVID-19 vaccine. JAAD Case Rep. 2021;18:49-50.doi:10.1016/j.jdcr.2021.10.017

34722839

63.

Myrdal

CN.

Culpepper

KS.

Leyo DuPont

. Generalized dermal hypersensitivity reaction following Moderna COVID-19 vaccination. Dermatol Ther. 2021;34(6):e15173 doi:10.1111/dth.15173

34676639

64.

Farinazzo

Ponis

Zelin

et al. Cutaneous adverse reactions after m-RNA COVID-19 vaccine: early reports from Northeast Italy. J Eur Acad Dermatol Venereol. 2021;35(9):e548-e551.doi:10.1111/jdv.17343

34021625

65.

Peigottu

MF.

Ferreli

Atzori

MG.

Atzori

. Skin adverse reactions to novel messenger RNA coronavirus vaccination: a case series. Diseases. 2021;9(3):58.doi:10.3390/diseases9030058

34562965

66.

Choi

Liew

CF.

Oon

. Cutaneous adverse effects and contraindications to COVID-19 vaccination; four cases and an illustrative review from an Asian country. Dermatol Ther. 2021;34(6):e15123 doi:10.1111/dth.15123

34478204

67.

Akdaş

Öğüt

Öztaş

MO.

İlter

. Cutaneous reactions following Sinovac (CoronaVac) COVID‐19 vaccination: a case series of six healthcare workers from a single centre. Acad Dermatol Venereol. 2021;35(12):e861-e864.doi:10.1111/jdv.17592

68.

Annabi

Dupin

Sohier

et al. Rare cutaneous adverse effects of COVID-19 vaccines: a case series and review of the literature. J Eur Acad Dermatol Venereol. 2021;35(12):e847-e850.doi:10.1111/jdv.17578

34363637

69.

Sernicola

Dybala

Gomes

et al. Lymphomatoid drug reaction developed after BNT162b2 (Comirnaty) COVID-19 vaccine manifesting as pityriasis lichenoides et varioliformis acuta-like eruption. J Eur Acad Dermatol Venereol. 2022;36(3):e172-e174.doi:10.1111/jdv.17807

34751995

70.

Hunjan

MK.

Roberts

Karim

Hague

. Pityriasis rubra pilaris-like eruption following administration of the BNT163b2 (Pfizer-BioNTech) mRNA COVID-19 vaccine. Clin Exp Dermatol. 2022;47(1):188-190.doi:10.1111/ced.14878

34379821

71.

Leerunyakul

Pakornphadungsit

Suchonwanit

. Case report: pityriasis Rosea-Like eruption following COVID-19 vaccination. Front Med. 2021;8:752443.doi:10.3389/fmed.2021.752443

34557507

72.

Leasure

AC.

Cowper

SE.

McNiff

Cohen

. Generalized eczematous reactions to the Pfizer-BioNTech COVID-19 vaccine. J Eur Acad Dermatol Venereol. 2021;35(11):e716-e717.doi:10.1111/jdv.17494

34236729

73.

Sandhu

Bhatnagar

Kumar

et al. Leukocytoclastic vasculitis as a cutaneous manifestation of ChAdOx1 nCoV-19 corona virus vaccine (recombinant. Dermatol Ther. 2021;34(6):e15141 doi:10.1111/dth.15141

34546608

74.

Shahrigharahkoshan

Gagnon

LP.

Mathieu

. Cutaneous leukocytoclastic vasculitis induction following ChAdOx1 nCoV-19 vaccine. Cureus. 2021;13(10):e19005 doi:10.7759/cureus.19005

34853744

75.

Jin

WJ.

Ahn

SW.

Jang

SH.

Hong

SM.

Seol

JE.

Kim

. Leukocytoclastic vasculitis after coronavirus disease 2019 vaccination. J Dermatol. 2022;49(1):e34-e35.doi:10.1111/1346-8138.16212

34713472

76.

Fiorillo

Pancetti

Cortese

et al. Leukocytoclastic vasculitis (cutaneous small-vessel vasculitis) after COVID-19 vaccination. J Autoimmun. 2022;127:102783 doi:10.1016/j.jaut.2021.102783

34973526

77.

Kharkar

Vishwanath

Mahajan

Joshi

Gole

. Asymmetrical cutaneous vasculitis following COVID-19 vaccination with unusual eosinophil preponderance. Clin Exp Dermatol. 2021;46(8):1596-1597.doi:10.1111/ced.14797

34115904

78.

Torrealba-Acosta

Martin

JC.

Huttenbach

et al. Acute encephalitis, myoclonus and sweet syndrome after mRNA-1273 vaccine. BMJ Case Rep. 2021;14(7):e243173 doi:10.1136/bcr-2021-243173

34312136

79.

Baffa

ME.

Maglie

Giovannozzi

et al. Sweet syndrome following SARS-CoV2 vaccination. Vaccines. 2021;9(11):1212.doi:10.3390/vaccines9111212

34835143

80.

Majid

Mearaj

. Sweet syndrome after Oxford‐AstraZeneca COVID ‐19 vaccine (AZD1222) in an elderly female. Dermatol Ther. 2021;34(6):e15146 doi:10.1111/dth.15146

34590397

81.

Žagar

Hlača

Brajac

Prpić-Massari

Peternel

Kaštelan

. Bullous sweet syndrome following SARS-CoV-2 Oxford AstraZeneca vaccine. Br J Dermatol. 2022;186(3):e110 doi:10.1111/bjd.20876

34817862

82.

Afacan

Öğüt

Üstün

Şentürk

Yazıcı

Adışen

. Radiation recall dermatitis triggered by inactivated COVID-19 vaccine. Clin Exp Dermatol. 2021;46(8):1582-1584.doi:10.1111/ced.14786

34080223

83.

Villagrasa-Boli

Monte-Serrano

Martínez-Cisneros

et al. Papular acrodermatitis of childhood-like eruption triggered by SARS-CoV-2 vaccination: report of two cases. Dermatol Ther. 2022;35(2):e15252 doi:10.1111/dth.15252

34877762

84.

Agaronov

Makdesi

Hall

. Acute generalized exanthematous pustulosis induced by Moderna COVID-19 messenger RNA vaccine. JAAD Case Rep. 2021;16:96-97.doi:10.1016/j.jdcr.2021.08.013

34466640

85.

Bakir

Almeshal

Alturki

Obaid

Almazroo

. Toxic epidermal necrolysis post COVID-19 vaccination - first reported case. Cureus. 2021;13(8):e17215 doi:10.7759/cureus.17215

34540442

86.

Elboraey

MO.

Essa

EESF

. Stevens-Johnson syndrome post second dose of pfizer COVID-19 vaccine: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol. 2021;132(4):e139-e142.doi:10.1016/j.oooo.2021.06.019

34384729

87.

Dash

Sirka

CS.

Mishra

Viswan

. COVID-19 vaccine-induced Stevens-Johnson syndrome. Clin Exp Dermatol. 2021;46(8):1615-1617.doi:10.1111/ced.14784

34081806

88.

Gruenstein

Levitt

. Skin necrosis at both COVID-19 vaccine injection sites. JAAD Case Rep. 2021;15:67-68.doi:10.1016/j.jdcr.2021.07.022

34337117

89.

Kaminetsky

Rudikoff

. New‐onset vitiligo following mRNA-1273 (Moderna) COVID-19 vaccination. Clin Case Rep. 2021;9(9):e04865 doi:10.1002/ccr3.4865

34603727

90.

Merhy

Sarkis

A-S.

Kaikati

El Khoury

Ghosn

Stephan

. New‐onset cutaneous lichen planus triggered by COVID-19 vaccination. J Eur Acad Dermatol Venereol. 2021;35(11):e729-e730.doi:10.1111/jdv.17504

34236718

91.

Wunderlich

Dirschka

. Erythema exsudativum multiforme infolge einer COVID-19-Impfung (BNT162b2. Hautarzt. 2022;73(1):68-70.doi:10.1007/s00105-021-04911-4

92.

LeWitt

Chung

Manton

et al. Rare lymphomatoid reactions following SARS-CoV-2 vaccination. JAAD Case Rep. 2022;20:26-30.doi:10.1016/j.jdcr.2021.11.021

34926748

93.

Niebel

Ralser-Isselstein

Jaschke

Braegelmann

Bieber

Wenzel

. Exacerbation of subacute cutaneous lupus erythematosus following vaccination with BNT162b2 mRNA vaccine. Dermatol Ther. 2021;34(4):e15017 doi:10.1111/dth.15017

34075664

94.

Kreuter

Licciardi-Fernandez

MJ.

Burmann

S-N.

Burkert

Oellig

Michalowitz

A-L

. Induction and exacerbation of subacute cutaneous lupus erythematosus following mRNA-based or adenoviral vector-based SARS-CoV-2 vaccination. Clin Exp Dermatol. 2022;47(1):161-163.doi:10.1111/ced.14858

34291477

95.

Onn

P-Y.

Chang

. Lichenoid cutaneous skin eruption and associated systemic inflammatory response following Pfizer-BioNTech mRNA COVID-19 vaccine administration. Respirol Case Rep. 2021;9(11):e0860 doi:10.1002/rcr2.860

34631106

96.

Ziraldo

Theate

Vanhooteghem

. Drug-induced lichenoid exanthema by a vaccine against COVID-19 (Vaxzevria. Dermatol Reports. 2021;13(3):9358 doi:10.4081/dr.2021.9358

34880971

97.

Piccolo

Bassi

Mazzatenta

et al. COVID vaccine-induced reaction around molluscum contagiosum with secondary partial clearance of lesions. J Eur Acad Dermatol Venereol. 2022;36(5):e335-e337.doi:10.1111/jdv.17919

35020227

98.

Shah

KM.

West

Simpson

Rainwater

. Cutaneous mucormycosis following COVID-19 vaccination in a patient with bullous pemphigoid. JAAD Case Rep. 2021;15:80-81.doi:10.1016/j.jdcr.2021.06.012

34222572

99.

Herrera

West

Holstein

. Erythema NODOSUM-LIKE rash after SARS-COV-2 vaccination: a case report. Chest. 2021;160(4):A1380 doi:10.1016/j.chest.2021.07.1261

100.

Berry

CT.

Eliliwi

Gallagher

et al. Cutaneous small vessel vasculitis following single-dose Janssen Ad26.COV2.S vaccination. JAAD Case Rep. 2021;15:11-14.doi:10.1016/j.jdcr.2021.07.002

34337124

101.

Hidaka

Ogasawara

Sugimura

et al. New-onset Evans syndrome associated with systemic lupus erythematosus after BNT162b2 mRNA COVID-19 vaccination. Int J Hematol. 2022;115(3):424-427.doi:10.1007/s12185-021-03243-2

34687421

102.

Popatia

Chiu

. Vulvar aphthous ulcer after COVID-19 vaccination. Pediatr Dermatol. 2022;39(1):153-154.doi:10.1111/pde.14881

34888935

103.

Osmond

Kenny

. Reaction to dermal filler following COVID-19 vaccination. J Cosmet Dermatol. 2021;20(12):3751-3752.doi:10.1111/jocd.14566

34706150

104.

Michon

. Hyaluronic acid soft tissue filler delayed inflammatory reaction following COVID-19 vaccination – A case report. J Cosmet Dermatol. 2021;20(9):2684-2690.doi:10.1111/jocd.14312

34174156

105.

Savva

Battineni

Amenta

Nittari

. Hypersensitivity reaction to hyaluronic acid dermal filler after the Pfizer vaccination against SARS-CoV-2. Int J Infect Dis. 2021;113:233-235.doi:10.1016/j.ijid.2021.09.066

34597761

106.

Rubin

LG.

Levin

MJ.

Ljungman

et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58(3):309-318.doi:10.1093/cid/cit816

24421306

107.

Shokouhi

Hakamifard

. COVID-19 vaccine and corticosteroids: a challenging issue. Eur J Inflamm. 2021 doi:205873922110661

108.

Curtis

JR.

Johnson

SR.

Anthony

DD.

Arasaratnam

RJ.

Baden

LR.

Bass

. American College of Rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases – version 4. Arthritis Rheumatol. 2022;73(10):e60-e75.doi:10.1002/art.42109

109.

Deepak

Kim

Paley

MA.

Yang

Carvidi

AB.

El-Qunni

. Glucocorticoids and B cell depleting agents substantially impair immunogenicity of mRNA vaccines to SARS-CoV-2. Infectious Diseases. 2021 doi:10.1101/2021.04.05.21254656

110.

Yang

J-H.

Baek

et al. Effects of short-term corticosteroid use on reactogenicity and immunogenicity of the first dose of ChAdOx1 nCoV-19 vaccine. Front Immunol. 2021;12:744206 doi:10.3389/fimmu.2021.744206

34630425

111.

Zwar

. Travel and immunosuppressant medication. Aust J Gen Pract. 2020;49(3):88-92.doi:10.31128/AJGP-11-19-5146

32113206

112.

Siegel

CA.

Melmed

GY.

McGovern

et al. SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting. Gut. 2021;70(4):635-640.doi:10.1136/gutjnl-2020-324000

33472895

113.

National Psoriasis Foundation: COVID-19 Task Force Guidance Statements . Portland, OR: Updated on April 1, 2021. https://www.psoriasis.org/covid-19-task-force-guidance-statements/

114.

Rabinowich

Grupper

Baruch

et al. Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients. J Hepatol. 2021;75(2):435-438.doi:10.1016/j.jhep.2021.04.020

33892006

115.

Lee

ARYB.

Wong

SY.

Chai

LYA

et al. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis. BMJ. 2022;376:e068632 doi:10.1136/bmj-2021-068632

35236664

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

1.17 MB